James K. Hennan

1.8k total citations
45 papers, 1.4k citations indexed

About

James K. Hennan is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Hematology. According to data from OpenAlex, James K. Hennan has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cardiology and Cardiovascular Medicine, 21 papers in Molecular Biology and 9 papers in Hematology. Recurrent topics in James K. Hennan's work include Cardiac electrophysiology and arrhythmias (21 papers), Connexins and lens biology (14 papers) and Ion channel regulation and function (9 papers). James K. Hennan is often cited by papers focused on Cardiac electrophysiology and arrhythmias (21 papers), Connexins and lens biology (14 papers) and Ion channel regulation and function (9 papers). James K. Hennan collaborates with scholars based in United States, Canada and Denmark. James K. Hennan's co-authors include Ketil Haugan, David L. Crandall, Benedict R. Lucchesi, Terrance D. Barrett, Jørgen S. Petersen, Hassan Elokdah, Robert E. Swillo, Jack Diamond, Morten Schak Nielsen and Anne Louise Kjølbye and has published in prestigious journals such as Circulation, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

James K. Hennan

45 papers receiving 1.4k citations

Peers

Countries citing papers authored by James K. Hennan

Since Specialization

Citations

This map shows the geographic impact of James K. Hennan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James K. Hennan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James K. Hennan more than expected).

Fields of papers citing papers by James K. Hennan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James K. Hennan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James K. Hennan. The network helps show where James K. Hennan may publish in the future.

Co-authorship network of co-authors of James K. Hennan

This figure shows the co-authorship network connecting the top 25 collaborators of James K. Hennan. A scholar is included among the top collaborators of James K. Hennan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James K. Hennan. James K. Hennan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension 2017 ·Cancer Chemotherapy and Pharmacology ·(unknown), Mausumee Guha, James K. Hennan, (unknown), (unknown), Damir Simic, Michael J. Graziano, (unknown), Thomas P. Sanderson, Roderick T. Bunch	12
2	From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor 2016 ·Toxicological Sciences ·Michael Gill, (unknown), James K. Hennan, (unknown), Denise I. Bounous, (unknown), John R. Megill, Evan B. Janovitz, Marc H. Davies, Thomas P. Sanderson, Michael J. Graziano	7
3	The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Eric I. Rossman, Kun Liu, (unknown), Robert E. Swillo, Julie A. Krueger, Stephen J. Gardell, John A. Butera, (unknown), Joel Kantrowitz, Hal S. Feldman, Jørgen S. Petersen, Ketil Haugan, James K. Hennan	48
4	Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis 2008 ·Journal of Thrombosis and Haemostasis ·James K. Hennan, (unknown), Robert E. Swillo, (unknown), (unknown), G P Vlasuk, Stephen J. Gardell, David L. Crandall	51
5	Enhancement of ventricular gap-junction coupling by rotigaptide 2008 ·Cardiovascular Research ·Xianming Lin, Christian W. Zemlin, James K. Hennan, Jørgen S. Petersen, Richard D. Veenstra	30
6	Pharmacological Modulation of Gap Junction Function with the Novel Compound Rotigaptide: A Promising New Principle for Prevention of Arrhythmias 2007 ·Basic & Clinical Pharmacology & Toxicology ·Anne Louise Kjølbye, Ketil Haugan, James K. Hennan, Jørgen S. Petersen	45
7	Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Patricia W. Bedard, Valérie Clerin, (unknown), Boris Tchernychev, (unknown), Christine Resmini, James C. Keith, James K. Hennan, Neelu Kaila, Silvano DeBernardo, Kristin Janz, Qin Wang, David L. Crandall, Robert G. Schaub, Gray D. Shaw, Laura Carter	38
8	GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II‐mediated pressor responses in Sprague–Dawley rats 2007 ·British Journal of Pharmacology ·Courtney E. Leik, (unknown), James K. Hennan, Michael Basso, (unknown), David L. Crandall, P Nambi	31
9	Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123) 2006 ·Journal of Molecular and Cellular Cardiology ·Lene Nygaard Axelsen, Martin Stahlhut, Shabaz Mohammed, Bjarne Due Larsen, Morten Schak Nielsen, Niels‐Henrik Holstein‐Rathlou, Søren Andersen, Ole N. Jensen, James K. Hennan, Anne Louise Kjølbye	113
10	The Antiarrhythmic Peptide Rotigaptide (ZP123) Increases Connexin 43 Protein Expression in Neonatal Rat Ventricular Cardiomyocytes 2006 ·Cell Communication & Adhesion ·Martin Stahlhut, (unknown), James K. Hennan, (unknown)	35
11	Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis 2006 ·Thrombosis and Haemostasis ·Robert E. Swillo, (unknown), Courtney E. Leik, Jonathan Brooks, Gray D. Shaw, Robert G. Schaub, David L. Crandall, George P. Vlasuk, James K. Hennan	35
12	Rotigaptide (ZP123) Reverts Established Atrial Conduction Velocity Slowing 2005 ·Cell Communication & Adhesion ·Ketil Haugan, Anne Louise Kjølbye, James K. Hennan, Jørgen S. Petersen	12
13	Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1 H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis 2005 ·Journal of Pharmacology and Experimental Therapeutics ·James K. Hennan, Hassan Elokdah, Mauricio Leal, Allena Ji, Gregory S. Friedrichs, (unknown), Robert E. Swillo, (unknown), (unknown), David L. Crandall	35
14	The Antiarrhythmic Peptide Analog ZP123 Prevents Atrial Conduction Slowing During Metabolic Stress 2005 ·Journal of Cardiovascular Electrophysiology ·Ketil Haugan, (unknown), (unknown), Jørgen S. Petersen, Niels‐Henrik Holstein‐Rathlou, James K. Hennan, Morten Schak Nielsen	58
15	Characterization and comparative evaluation of a structurally unique PAI‐1 inhibitor exhibiting oral in‐vivo efficacy 2004 ·Journal of Thrombosis and Haemostasis ·David L. Crandall, Hassan Elokdah, Li Di, James K. Hennan, Natalia Gorlatova, Daniel A. Lawrence	38
16	WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation 2003 ·Biochemical and Biophysical Research Communications ·David L. Crandall, James K. Hennan, Hassan Elokdah, Girija Krishnamurthy, (unknown), (unknown), (unknown), Robert E. Swillo	10
17	Intimatan Prevents Arterial and Venous Thrombosis in a Canine Model of Deep Vessel Wall Injury 2002 ·Journal of Pharmacology and Experimental Therapeutics ·James K. Hennan, (unknown), (unknown), Edward M. Driscoll, Alan D. Cardin, Benedict R. Lucchesi	18
18	Tedisamil and dofetilide‐induced torsades de pointes, rate and potassium dependence 2001 ·British Journal of Pharmacology ·Terrance D. Barrett, James K. Hennan, Peter Fischbach, Brian Patrick O’Neill, Edward M. Driscoll, Benedict R. Lucchesi	16
19	Conversion of Atrial Fibrillation by the Experimental Antiarrhythmic Drug Tedisamil in Two Canine Models 2001 ·Journal of Cardiovascular Electrophysiology ·Peter Fischbach, Terrance D. Barrett, Rajiva Goyal, B.C. Tran, (unknown), James K. Hennan, Benedict R. Lucchesi	10
20	An updated two-dimensional gel electrophoresis technique for the detection of drug-induced changes in protein phosphorylation in intact smooth muscle 1999 ·Journal of Pharmacological and Toxicological Methods ·James K. Hennan, Jack Diamond	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact